Published in J Neurosci on August 30, 2006
Animal models of neuropsychiatric disorders. Nat Neurosci (2010) 5.78
Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther (2007) 2.62
GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci (2011) 1.99
How might circadian rhythms control mood? Let me count the ways... Biol Psychiatry (2013) 1.95
Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology (2010) 1.87
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry (2009) 1.71
Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry (2010) 1.70
What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis (2011) 1.65
Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology (2010) 1.61
Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci (2011) 1.48
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull (2009) 1.45
Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain (2009) 1.44
Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol (2010) 1.39
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36
Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry (2008) 1.36
Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am J Med Genet B Neuropsychiatr Genet (2008) 1.35
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans (2009) 1.27
Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest (2011) 1.20
Sex differences in animal models of psychiatric disorders. Br J Pharmacol (2014) 1.15
Circadian rhythms and mood regulation: insights from pre-clinical models. Eur Neuropsychopharmacol (2011) 1.13
Human genes involved in copy number variation: mechanisms of origin, functional effects and implications for disease. Cytogenet Genome Res (2009) 1.13
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci (2012) 1.12
Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci U S A (2012) 1.10
TNiK is required for postsynaptic and nuclear signaling pathways and cognitive function. J Neurosci (2012) 1.10
Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology (2009) 1.08
AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology (2011) 1.08
5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal (2010) 1.06
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci (2012) 1.02
The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav (2010) 1.02
Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem (2007) 1.00
Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol Neurosci (2011) 1.00
Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse (2011) 0.99
Functions of GSK-3 Signaling in Development of the Nervous System. Front Mol Neurosci (2011) 0.99
A role for WNT/β-catenin signaling in the neural mechanisms of behavior. J Neuroimmune Pharmacol (2012) 0.97
Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev (2010) 0.97
Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl Psychiatry (2013) 0.97
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Deletion of glutamate delta-1 receptor in mouse leads to aberrant emotional and social behaviors. PLoS One (2012) 0.95
Reverse translational strategies for developing animal models of bipolar disorder. Dis Model Mech (2009) 0.94
Diacylglycerol kinase β knockout mice exhibit lithium-sensitive behavioral abnormalities. PLoS One (2010) 0.94
GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration. Int J Alzheimers Dis (2011) 0.94
Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav (2014) 0.94
Calcium-sensitive adenylyl cyclases in depression and anxiety: behavioral and biochemical consequences of isoform targeting. Biol Psychiatry (2008) 0.94
Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions. Proc Natl Acad Sci U S A (2008) 0.93
Cocaine regulates protein kinase B and glycogen synthase kinase-3 activity in selective regions of rat brain. J Neurochem (2008) 0.91
Protein Phosphatase 2a and glycogen synthase kinase 3 signaling modulate prepulse inhibition of the acoustic startle response by altering cortical M-Type potassium channel activity. J Neurosci (2010) 0.91
Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry (2010) 0.91
Reduced anxiety and depression-like behaviours in the circadian period mutant mouse afterhours. PLoS One (2012) 0.91
GSK-3/Shaggy regulates olfactory habituation in Drosophila. Proc Natl Acad Sci U S A (2007) 0.90
Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology (2010) 0.90
Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci (2013) 0.88
Lithium promotes neural precursor cell proliferation: evidence for the involvement of the non-canonical GSK-3β-NF-AT signaling. Cell Biosci (2011) 0.88
GSK-3β activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev (2010) 0.88
Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.87
Dopamine receptors - IUPHAR Review 13. Br J Pharmacol (2015) 0.87
Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry (2014) 0.86
Disruption of the circadian output molecule prokineticin 2 results in anxiolytic and antidepressant-like effects in mice. Neuropsychopharmacology (2008) 0.85
Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of Tourette syndrome. Eur Neuropsychopharmacol (2014) 0.85
Annual Research Review: Transgenic mouse models of childhood-onset psychiatric disorders. J Child Psychol Psychiatry (2011) 0.84
Altered dopamine signaling in naturally occurring maternal neglect. PLoS One (2008) 0.84
SCOP/PHLPP1β in the basolateral amygdala regulates circadian expression of mouse anxiety-like behavior. Sci Rep (2016) 0.83
Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior. Neurosci Biobehav Rev (2014) 0.83
Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse. Behav Brain Res (2012) 0.83
Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Mol Psychiatry (2013) 0.83
Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol (2013) 0.83
Modeling and validating chronic pharmacological manipulation of circadian rhythms. CPT Pharmacometrics Syst Pharmacol (2013) 0.83
Enhanced catecholamine release in mice expressing PKB/SGK-resistant GSK3. Pflugers Arch (2011) 0.82
Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase. Mol Brain (2013) 0.82
Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord (2010) 0.81
Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia. Int J Neuropsychopharmacol (2010) 0.81
Circadian Forced Desynchrony of the Master Clock Leads to Phenotypic Manifestation of Depression in Rats. eNeuro (2017) 0.81
Region-specific dysregulation of glycogen synthase kinase-3β and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia. Bipolar Disord (2014) 0.80
Hyperactivity, startle reactivity and cell-proliferation deficits are resistant to chronic lithium treatment in adult Nr2e1(frc/frc) mice. Genes Brain Behav (2010) 0.79
Forebrain-specific deletion of Cdk5 in pyramidal neurons results in mania-like behavior and cognitive impairment. Neurobiol Learn Mem (2013) 0.79
The wnt pathway in mood disorders. Curr Neuropharmacol (2012) 0.79
Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice. Eur J Pharmacol (2012) 0.79
Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Transl Psychiatry (2014) 0.78
Lithium's role in neural plasticity and its implications for mood disorders. Acta Psychiatr Scand (2013) 0.78
Behavioral abnormalities observed in Zfhx2-deficient mice. PLoS One (2012) 0.78
Animal models of bipolar mania: The past, present and future. Neuroscience (2015) 0.78
Insights into the Pathology of the α3 Na(+)/K(+)-ATPase Ion Pump in Neurological Disorders; Lessons from Animal Models. Front Physiol (2016) 0.77
NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens. J Neurochem (2010) 0.77
Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. Int J Mol Sci (2015) 0.76
Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases: An Update. Front Cell Dev Biol (2016) 0.76
The antidepressant roles of Wnt2 and Wnt3 in stress-induced depression-like behaviors. Transl Psychiatry (2016) 0.76
Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium response. Int J Bipolar Disord (2014) 0.76
Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect (2014) 0.76
Partial rodent genetic models for bipolar disorder. Curr Top Behav Neurosci (2011) 0.76
Modeling mania in preclinical settings: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr Dis Treat (2016) 0.75
A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Curr Neuropharmacol (2015) 0.75
Gsk3 Signalling and Redox Status in Bipolar Disorder: Evidence from Lithium Efficacy. Oxid Med Cell Longev (2016) 0.75
The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. Transl Psychiatry (2017) 0.75
Molecular Mechanisms of Bipolar Disorder: Progress Made and Future Challenges. Front Cell Neurosci (2017) 0.75
Loss of cyclin-dependent kinase 5 from parvalbumin interneurons leads to hyperinhibition, decreased anxiety, and memory impairment. J Neurosci (2015) 0.75
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet (2004) 2.61
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron (2012) 2.49
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci (2003) 2.37
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation (2009) 2.05
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem (2005) 2.03
Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol (2005) 2.00
Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci (2002) 1.94
Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. J Neurosci (2006) 1.54
NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology (2011) 1.16
Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol (2007) 1.15
Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci (2002) 1.15
Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur J Pharmacol (2007) 1.13
Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Gastroenterology (2006) 1.12
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res (2009) 1.09
In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery. Prog Neurobiol (2010) 1.05
Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem (2003) 1.05
Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol (2004) 1.04
Mammalian Navigators are microtubule plus-end tracking proteins that can reorganize the cytoskeleton to induce neurite-like extensions. Cell Motil Cytoskeleton (2009) 1.03
Role of ghrelin in the relationship between hyperphagia and accelerated gastric emptying in diabetic mice. Gastroenterology (2008) 1.03
Nonsyndromic hearing loss. Ear Hear (2003) 1.00
Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology (2011) 0.98
Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. J Med Chem (2013) 0.97
IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology (2007) 0.96
Impairment of VGLUT2 but not VGLUT1 signaling reduces neuropathy-induced hypersensitivity. Eur J Pain (2009) 0.96
Exposure to high- and low-light conditions in an open-field test of anxiety increases c-Fos expression in specific subdivisions of the rat basolateral amygdaloid complex. Brain Res Bull (2006) 0.95
Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Top Behav Neurosci (2010) 0.95
LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. J Cell Sci (2015) 0.95
Progression of low-frequency sensorineural hearing loss (DFNA6/14-WFS1). Arch Otolaryngol Head Neck Surg (2003) 0.95
Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med (2010) 0.95
Autosomal dominant low-frequency hearing impairment (DFNA6/14): a clinical and genetic family study. Otol Neurotol (2002) 0.94
Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett (2012) 0.94
Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci (2002) 0.94
Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol Endocrinol (2008) 0.94
Sex-related hearing impairment in Wolfram syndrome patients identified by inactivating WFS1 mutations. Audiol Neurootol (2003) 0.93
Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. Eur J Pharmacol (2010) 0.93
Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅). J Med Chem (2014) 0.92
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. Psychopharmacology (Berl) (2013) 0.91
Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels. Neurosci Lett (2005) 0.91
Cholinergic blockade impairs performance in operant DNMTP in two inbred strains of mice. Pharmacol Biochem Behav (2002) 0.90
A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. Int J Neuropsychopharmacol (2010) 0.90
Sensory deficits in mice hypomorphic for a mammalian homologue of unc-53. Brain Res Dev Brain Res (2004) 0.89
Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study. Neurobiol Dis (2011) 0.89
Nav2 is necessary for cranial nerve development and blood pressure regulation. Neural Dev (2010) 0.89
The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. BMC Res Notes (2012) 0.89
Selective modulation of coupled ryanodine receptors during microdomain activation of calcium/calmodulin-dependent kinase II in the dyadic cleft. Circ Res (2013) 0.88
Molecular characterization of WFS1 in patients with Wolfram syndrome. J Mol Diagn (2003) 0.87
Early exercise training after myocardial infarction prevents contractile but not electrical remodelling or hypertrophy. Cardiovasc Res (2009) 0.86
Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology (Berl) (2013) 0.86
Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice. Brain Res Mol Brain Res (2004) 0.85
Transcriptional response to corticotropin-releasing factor in AtT-20 cells. Mol Pharmacol (2004) 0.85
Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology (2006) 0.85
Stress-induced hyperthermia in the mouse: c-fos expression, corticosterone and temperature changes. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.85
Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. J Pharm Biomed Anal (2012) 0.84
Nav2 hypomorphic mutant mice are ataxic and exhibit abnormalities in cerebellar development. Dev Biol (2011) 0.83
GABAA-benzodiazepine receptor complex ligands and stress-induced hyperthermia in singly housed mice. Pharmacol Biochem Behav (2002) 0.83
Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol (2008) 0.82
Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia. Behav Brain Res (2011) 0.82
Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Drug Metab Dispos (2013) 0.82
Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Bioorg Med Chem Lett (2012) 0.82
Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. Mol Ther (2010) 0.81
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) (2009) 0.81
Decreased expression of multidrug efflux transporters in the brains of GSK-3beta transgenic mice. Brain Res (2009) 0.80
Touching on translation. Cell Tissue Res (2013) 0.80
The anxiogenic drug FG-7142 increases serotonin metabolism in the rat medial prefrontal cortex. Pharmacol Biochem Behav (2006) 0.80
Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs. J Pharmacol Exp Ther (2014) 0.79
Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) (2010) 0.79
The high-level similarity of some disparate gene expression measures. Bioinformatics (2007) 0.79
Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents. Neurotherapeutics (2012) 0.79
Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem (2011) 0.78
In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization. Peptides (2009) 0.78
Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J Pharmacol Exp Ther (2008) 0.78
Haploinsufficiency of VGluT1 but not VGluT2 impairs extinction of spatial preference and response suppression. Behav Brain Res (2013) 0.78
Stress-induced decreases in local cerebral glucose utilization in specific regions of the mouse brain. BMC Res Notes (2011) 0.77
A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependent. J Biopharm Stat (2005) 0.77
Pharmacologic treatment of panic disorder. Curr Top Behav Neurosci (2010) 0.77
Behavioral neurobiology of anxiety and its treatment. Preface. Curr Top Behav Neurosci (2010) 0.76
R278995/CRA0450, a corticotropin-releasing factor (CRF(1)) receptor antagonist modulates REM sleep measures in rats: Implication for therapeutic indication. Eur J Pharmacol (2012) 0.76
Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism. Bioorg Med Chem (2007) 0.76
Early life stress and psychopharmacology. Psychopharmacology (Berl) (2011) 0.76
Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. J Med Chem (2005) 0.76
Rational design and synthesis of aminopiperazinones as β-secretase (BACE) inhibitors. Bioorg Med Chem Lett (2011) 0.76